Oncotarget

Research Papers:

Multi-walled carbon nanotubes complement the anti-tumoral effect of 5-Fluorouracil

Eloisa González-Lavado, Lourdes Valdivia, Almudena García-Castaño, Fernando González, Carmen Pesquera, Rafael Valiente and Mónica L. Fanarraga _

PDF  |  Full Text  |  Supplementary Files  |  How to cite

Oncotarget. 2019; 10:2022-2029. https://doi.org/10.18632/oncotarget.26770

Metrics: PDF 1407 views  |   Full Text 1785 views  |   ?  


Abstract

Eloisa González-Lavado1, Lourdes Valdivia1, Almudena García-Castaño3, Fernando González1, Carmen Pesquera1, Rafael Valiente1,2 and Mónica L. Fanarraga1

1 Grupo de Nanomedicina, IDIVAL-Universidad de Cantabria, 39011, Santander, Spain

2 Dpto. Física Aplicada, Facultad de Ciencias, Universidad de Cantabria, 39011, Santander, Spain

3 Unidad De Ensayos Clínicos, Oncología Médica y Medicina Paliativa, Hospital Valdecilla-IDIVAL 39011, Santander, Spain

Correspondence to:

Mónica L. Fanarraga,email: [email protected]

Keywords: nanomaterial; nanocarrier; drug delivery; combined therapy; microtubule dynamics

Received: January 31, 2019     Accepted: February 19, 2019     Published: March 12, 2019

ABSTRACT

Multiple-drug resistance in human cancer is a major problem. To circumvent this issue, clinicians combine several drugs. However, this strategy could backfire resulting in more toxic or ineffective treatments. Carbon nanotubes (CNTs), and particularly multi-walled nanotubes (MWCNTs), display intrinsic properties against cancer interfering with microtubule dynamics and triggering anti-proliferative, anti-migratory and cytotoxic effects in vitro that result in tumor growth inhibition in vivo. Remarkably, these effects are maintained in tumors resistant to traditional microtubule-binding chemotherapies such as Taxol®.

In the view of these properties, we investigate the use of MWCNTs in the development of active-by-design nanocarriers, attempting to enhance the effect of broadly-used chemotherapies. We compare the cytotoxic and the anti-tumoral effect of 5-Fluorouracil (5-FU) -an antimetabolite treatment of various forms of cancer- with that of the drug physisorbed onto MWCNTs. Our results demonstrate how the total effect of the drug 5-FU is remarkably improved (50% more effective) when delivered intratumorally coupled to MWCNTs both in vitro and in vivo in solid tumoral models. Our results demonstrate how using MWCNTs as anti-cancer drug delivery platforms is a promising approach to boost the efficacy of traditional chemotherapies, while considerably reducing the chances of resistance in cancer cells.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 26770